Poor
Mostly Unaligned
Patient Risk:
Moderate
Summary
Most claims are absent from the provided FDA-approved prescribing information excerpt (which contains only indications). Several non-label forecasting/patent/cost statements are included, and the two indication-related claims are only partially aligned in wording/phrasing with Section 1.
Category Scores
Accurate Statements
Lurasidone is used to treat schizophrenia in adults and adolescents.
Supported by Section 1 (treatment of adult and adolescent patients [13 to 17 years] with schizophrenia).
Lurasidone is used to treat major depressive episode associated with bipolar I disorder (bipolar depression) as monotherapy in adult and pediatric patients (10 to 17 years).
Supported by Section 1 (monotherapy treatment of adult and pediatric patients [10 to 17 years] with major depressive episode associated with bipolar I disorder).
Unsupported Statements
Lurasidone (Latuda) is expected to face generic competition starting in 2023 and continuing into 2024.
Generic-competition timing is not stated in the provided label excerpt.
The shift toward generic competition follows the expiration of key patents and exclusivity periods for lurasidone.
Patent/exclusivity status and market timing are not described in the provided label excerpt.
The primary patents and exclusivity for lurasidone have expired or are nearing expiry.
Patent/exclusivity status is not included in the provided label excerpt.
Some patents related to lurasidone have already been invalidated or will expire soon.
Patent invalidation/expiry is not part of the provided label excerpt.
The period of uncertainty for generic launches of lurasidone extends through 2024.
Forecasts about generic-launch uncertainty are not present in the provided label excerpt.
Generic drug launch is typically contingent on patent expiry or successful patent challenges.
General policy/market mechanism statements are not part of the provided label excerpt.
Generic versions of lurasidone are expected to become available following the expiration of the drug's core patent protections.
Predictions about generic availability are not prescribing-information content in the provided label excerpt.
The introduction of generic lurasidone is expected to significantly lower the cost of the medication.
Economic/projection statements about generic cost are not in the provided label excerpt.
Contradictions
Important Omissions
No dosage/administration, contraindications, boxed warnings, warnings/precautions, drug interactions, adverse reactions, or monitoring details were evaluated because only the Indications section excerpt was provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the non-label forecasting statements (patents/generics/pricing) are unlikely to directly change dosing, they are not supported by the provided FDA-approved prescribing information and could mislead regarding product availability/cost. Indication phrasing is also only partially aligned with the label wording.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Multiple claims are patent/generic-market and cost forecasts that are absent from the FDA-approved prescribing information excerpt; two indication claims are only partially consistent with Section 1 wording.
Suggested Improvement
Remove or qualify all generic-competition/patent-timeline/cost statements as they are not supported by the provided label. For clinical indications, use the label’s exact phrasing where possible (e.g., “treatment…with schizophrenia,” and “major depressive episode associated with bipolar I disorder (bipolar depression)” and the stated age ranges).